Loxo Oncology, Inc.

Loxo Oncology, Inc. insiders are currently net sellers of LOXO stock, showing bearish sentiment over the past 90 days. Total sales of $540.9M outpace purchases of $95.9M, creating a net outflow of $445.0M.

Loxo Oncology, Inc. has 35 active insiders who have filed SEC Form 4 transactions in the past 90 days. Steve Elms (Executive) leads with 4 transactions totaling $522.0M. Andrew N. Schiff (Executive) follows with 1 transactions worth $251.2M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Loxo Oncology, Inc.'s current score of 15/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Feb 15, 2019, when H. Bilenker Joshua (Executive) disposed of 30,000 shares at $235.00 per share for $7.0M. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, LOXO insider trading sentiment is currently bearish with an Alignment Score of 15/100. The negative net flow of $445.0M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Loxo Oncology, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At LOXO, we track all Form 4 filings—currently showing 631 transactions from 35 insiders over 90 days.

A 10b5-1 plan allows Loxo Oncology, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At LOXO, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at LOXO appears discretionary, making insider signals more meaningful.

You can monitor Loxo Oncology, Inc. (LOXO) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 35 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Loxo Oncology, Inc.'s current score of 15/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $95.9M in purchases versus $540.9M in sales over 90 days, resulting in a net flow of -$445.0M.

SEC Form 4 filings are mandatory reports that Loxo Oncology, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At LOXO, the most common type is "S" with 34 occurrences. The most recent Form 4 was filed on Feb 15, 2019 by H. Bilenker Joshua.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Loxo Oncology, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at LOXO represents discretionary decisions with more informational value.